August 20, 2024 10:00 AM EDTUpdated 12:45 PM
Pharma
Health Tech

Big em­ploy­ers are spend­ing even more mon­ey on phar­ma­cy costs, dri­ven by GLP-1s and oth­er high-cost ther­a­pies, sur­vey says

Ngai Yeung

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

Phar­ma­cy costs are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times